- Home
- QTWO vs LEGN Comparison
QTWO vs LEGN Comparison
Compare QTWO & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QTWO
- LEGN
- Stock Information
- Founded
- QTWO 2004
- LEGN 2014
- Country
- QTWO United States
- LEGN United States
- Employees
- QTWO N/A
- LEGN N/A
- Industry
- QTWO Computer Software: Prepackaged Software
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- QTWO Technology
- LEGN Health Care
- Exchange
- QTWO Nasdaq
- LEGN Nasdaq
- Market Cap
- QTWO 5.8B
- LEGN 5.4B
- IPO Year
- QTWO 2014
- LEGN 2020
- Fundamental
- Price
- QTWO $89.17
- LEGN $43.36
- Analyst Decision
- QTWO Buy
- LEGN Strong Buy
- Analyst Count
- QTWO 17
- LEGN 11
- Target Price
- QTWO $102.81
- LEGN $74.60
- AVG Volume (30 Days)
- QTWO 459.3K
- LEGN 1.5M
- Earning Date
- QTWO 07-30-2025
- LEGN 08-08-2025
- Dividend Yield
- QTWO N/A
- LEGN N/A
- EPS Growth
- QTWO N/A
- LEGN N/A
- EPS
- QTWO N/A
- LEGN N/A
- Revenue
- QTWO $720,691,000.00
- LEGN $728,303,000.00
- Revenue This Year
- QTWO $14.38
- LEGN $65.33
- Revenue Next Year
- QTWO $10.64
- LEGN $54.68
- P/E Ratio
- QTWO N/A
- LEGN N/A
- Revenue Growth
- QTWO 13.12
- LEGN 112.46
- 52 Week Low
- QTWO $61.51
- LEGN $27.34
- 52 Week High
- QTWO $112.82
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- QTWO 45.44
- LEGN 70.87
- Support Level
- QTWO $89.14
- LEGN $38.53
- Resistance Level
- QTWO $91.06
- LEGN $45.30
- Average True Range (ATR)
- QTWO 2.13
- LEGN 1.72
- MACD
- QTWO -0.44
- LEGN 0.35
- Stochastic Oscillator
- QTWO 18.88
- LEGN 79.65
About QTWO Q2 Holdings Inc.
Q2 Holdings Inc. is a provider of cloud-based virtual banking solutions for regional financial institutions to deliver mobile banking services to retail and commercial end-users who wish to bank anywhere and anytime. Its solutions operate on an integrated tablet-first platform which provides financial institutions a comprehensive view of account holder activity and meets the regulatory and security requirements applicable to the industry. The firm generates revenue from subscription-based arrangements for software offerings. A large majority of the firm's revenue is generated in the United States.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.